Featuring a slide presentation and related discussion from Dr Joshua Sabari, including the following topics: Recent updates from ASCO 2022 in the use of EGFR- and MET-targeted therapies (0:00) Targeting HER3 in patients with advanced non-small cell lung cancer (NSCLC) with and without EGFR mutations (16:04) Recent updates in therapy for patients with EGFR exon 20 insertion mutations (21:47) DESTINY-Lung04 trial: Trastuzumab deruxtecan for patients with HER2 exon 19 or 20 mutations (2921) Using mutational status in predicting patient benefit from chemoimmunotherapy (34:51) Immune checkpoint inhibition for patients with NSCLC with EGFR mutations (38:41) Combining novel agents with immune checkpoint inhibitors for patients with NSCLC and high PD-L1 expression (47:36) CME information and select publications

Ver todos los episodios